Related Experiment Video

Updated: Aug 9, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

The case for rituximab in AIDS-related lymphoma

Kieron Dunleavy, Wyndham H Wilson, Lawrence D Kaplan

    Blood
    |March 24, 2006
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Aug 9, 2026

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
    07:25

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

    Published on: May 4, 2017

    Related Concept Videos

    Retrovirus Life Cycles01:10

    Retrovirus Life Cycles

    Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

    Articles linked to this work by shared authors, journal, and citation graph.

    SOHO State of the Art Updates and Next Questions| Mediastinal Gray-zone Lymphoma: Novel Biologic Insights and Updates on How Best to Approach This Rare Entity.

    Clinical lymphoma, myeloma & leukemia·2026

    Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.

    Blood advances·2026

    Axes of biological variation in diffuse large B cell lymphoma.

    Cancer cell·2026

    Novel Molecular Insights and Evolution of Less Toxic Therapeutic Strategies in Burkitt Lymphoma.

    Cancers·2025

    Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

    A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies.

    Blood neoplasia·2025

    T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

    Blood·2026

    Ferroptotic stress promotes hematopoietic stem cell aging through S1P-dependent epigenetic and lipid remodeling.

    Blood·2026

    Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma.

    Blood·2026

    Whole genome sequencing to elucidate novel genetic modifiers of FVIII clearance.

    Blood·2026

    Early administration of calcineurin inhibitors limits tolerogenic effect of PTCy in allogeneic hematopoietic transplant.

    Blood·2026

    NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib.

    Blood·2026

    Intrasplenic Thymus Organogenesis from Injectable Tissue Fragments Restores Functional T-Cell Immunity.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma.

    European journal of haematology·2026

    Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case report.

    Immunotherapy·2026

    Macrophage metabolic reprogramming in organ transplantation: mechanisms, transplant outcomes, and therapeutic implications.

    Frontiers in cellular and infection microbiology·2026

    Low T3 Syndrome in Acute Myocardial Infarction: Association With Cardiac Biomarkers and Implications for Myocardial Injury Severity.

    Cureus·2026

    Real-world comparative evaluation of immune-related toxicities in non-small cell lung cancer patients treated with immune-checkpoint inhibitors in Greece and Sweden.

    Frontiers in immunology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us